Opus Genetics, Inc. (IRD) - Total Liabilities
Based on the latest financial reports, Opus Genetics, Inc. (IRD) has total liabilities worth $34.90 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check IRD asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Opus Genetics, Inc. - Total Liabilities Trend (2019–2025)
This chart illustrates how Opus Genetics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Opus Genetics, Inc.'s balance sheet.
Opus Genetics, Inc. Competitors by Total Liabilities
The table below lists competitors of Opus Genetics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
USA | $34.24 Million |
|
Grand Korea Leisure Co. Ltd
KO:114090
|
Korea | ₩181.32 Billion |
|
China Datang Corporation Renewable Power Co. Limited
STU:DT7
|
Germany | €77.60 Billion |
|
NACL Industries Limited
NSE:NACLIND
|
India | Rs-6.83 Billion |
|
Mirrabooka Investments Ltd
AU:MIR
|
Australia | AU$48.01 Million |
|
Anzheng Fashion
SHG:603839
|
China | CN¥880.56 Million |
|
Symtek Automation Asia Co Ltd
TW:6438
|
Taiwan | NT$4.76 Billion |
|
Hanil Cement Co Ltd
KO:003300
|
Korea | ₩1.37 Trillion |
Liability Composition Analysis (2019–2025)
This chart breaks down Opus Genetics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Opus Genetics, Inc. balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.43 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.69 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Opus Genetics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Opus Genetics, Inc. (2019–2025)
The table below shows the annual total liabilities of Opus Genetics, Inc. from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $34.90 Million | +15.78% |
| 2024-12-31 | $30.14 Million | +645.62% |
| 2023-12-31 | $4.04 Million | +46.82% |
| 2022-12-31 | $2.75 Million | -28.59% |
| 2021-12-31 | $3.85 Million | -87.62% |
| 2020-12-31 | $31.15 Million | +233.36% |
| 2019-12-31 | $9.34 Million | -- |
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 t… Read more